Intrapulmonary Shunt in the Course of Pediatric Liver Transplantation

Time-dependent reversal of significant intrapulmonary shunt after liver transplantation

“…Repeated cTTE and arterial blood gas analysis were done in 31 adult patients after successful LT and 100% of the HPS cases reversed within the first year post-LT [19]. This is consistent with other studies showing a 100% reversal rate in patients with HPS 6 to 18 months following LT [21,22].…”

“…In the literature, there were few clinical studies using repeated cTTE, from which limited information regarding the chronology of IPS or HPS reversibility after LT could be obtained [19,20]. The prevalence of IPS in pediatric patients who underwent LT was reported to be 16.8% (18/107) and IPS showed complete regression in all patients during follow-up in one study [19]. The mean duration of IPS was reported 5.8 months (range, 1 to 16).…”

Hepatopulmonary Syndrome in Children with Cirrhotic and Non-Cirrhotic Portal Hypertension: A Single-Center Experience

“…The reported prevalence of HPS in adult cirrhotic patients is between 4 and 19% [14,15]. The reported prevalence of HPS in children with Budd-Chiari syndrome, chronic liver disease, biliary atresia and polysplenia syndrome, and portal vein obstruction is 28,[8][9][10][11][12][13]20, and 0.5%, respectively, and 17-19% in liver transplant recipients [3,5,[16][17][18][19]. The differing prevalence of HPS is primarily due to the heterogeneity of the disease groups and the applied criteria for HPS [14][15][16][17][18].…”

Long‐term outcomes of pediatric living donor liver transplantation at a single institution

“…This study has several limitations, including the small patient population, the categorization of variables (e.g., severity or extent of rejection, PTLD, and viral infections were not included), and the selection of variables (e.g., hepatitis B infection and hepatopulmonary syndrome [39] were not included). In addition, PELD scores, UNOS status 1a and 1b, and hepatic encephalopathy overlap to a certain extent, and several variables, such as chronic rejection and PTLD, can be related to immunosuppression and can influence patient outcomes.…”